Lataa...
mTOR Inhibitors as Radiosensitizers in Neuroendocrine Neoplasms
Peptide receptor radioligand therapy (PRRT) has evolved as an important second-line treatment option in the management of inoperable and metastatic neuroendocrine neoplasms (NEN). Though high radiation doses can be delivered to the tumors, complete remission is still rare. Radiosensitization prior t...
Tallennettuna:
| Julkaisussa: | Front Oncol |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7897674/ https://ncbi.nlm.nih.gov/pubmed/33628728 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.578380 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|